Suppr超能文献

雾化喷他脒沉积的直接同位素评估:雾化器的影响。

Direct isotopic assessment of aerosolized pentamidine deposition: influence of nebuliser.

作者信息

Diot P, Le Pape A, Becquemin M H, Besnier J M, Boissinot E, Bastides F, Benjemaa M, Choutet P, Lemarie E

机构信息

Département des Maladies Respiratoires, CHU Bretonneau, Tours, France.

出版信息

Eur J Med. 1993 Oct-Nov;2(8):484-8.

PMID:8258049
Abstract

OBJECTIVES

The aim of the present study was to compare the efficiency of pulmonary deposition of pentamidine using the Respirgard II jet nebuliser or the Fison ultrasonic nebuliser with 99m technetium (99m Tc) labelled pentamidine in the current conditions of recommended treatment. The study was designed in three stages, to verify particle size distribution, to validate the isotope labelling, and to compare pulmonary deposition of pentamidine isethionate with the two nebulisers.

METHODS

Count median aerodynamic diameter and mass median aerodynamic diameter were measured using the velocimetry technique and aerosol dispersion was calculated according to the standard deviation defined by the ratio of diameters between 84.3% and 50% of the total distribution. Stability of labelling was checked both in vitro, by radiochromatography, and in vivo, by the absence of free technetium thyroid fixation after intravenous injection of the preparation to a rat and inhalation by baboons. The direct isotopic technique was used to compare pulmonary deposition of 300 mg aerosolized 99m Tc labelled pentamidine isothionate with the two nebulisers in four HIV patients treated with primary prophylaxis.

RESULTS

Count median aerodynamic diameter and mass median aerodynamic diameter (MMAD) were higher with Fisoneb than with Respirgard II. Nevertheless Fisoneb MMAD remained in the optimal range for peripheral deposition. In one patient, pentamidine lung burden was higher using the Respirgard II (13% of dose originally in nebuliser) when compared with the Fisoneb (10.2% of dose originally in nebuliser). A better result was obtained in the 3 other patients with Fisoneb (mean = 14.3%) compared with Respirgard II (mean = 3.8%). In all 4 patients gastric contamination was higher with Fisoneb (mean = 5.2%) as compared with Respirgard II (mean = 2.6%). Cough and bronchospasm were not observed with either device.

CONCLUSION

This study showed that Fisoneb, a practical and cheap nebuliser which has proved to be effective in clinical studies when used for pentamidine nebulisation, leads to correct particle size distribution and pulmonary deposition of the drug. We believe that such studies to evaluate aerosol characteristics should be recommended for any kind of nebuliser.

摘要

目的

本研究的目的是在推荐治疗的当前条件下,比较使用Respirgard II喷射雾化器或Fison超声雾化器将喷他脒与99m锝(99m Tc)标记的喷他脒进行肺部沉积的效率。该研究分三个阶段设计,以验证颗粒大小分布、验证同位素标记,并比较两种雾化器对乙磺酸盐喷他脒的肺部沉积情况。

方法

使用测速技术测量计数中值空气动力学直径和质量中值空气动力学直径,并根据由总分布的84.3%和50%之间的直径比定义的标准偏差计算气溶胶分散度。通过放射性色谱法在体外检查标记的稳定性,并通过将制剂静脉注射给大鼠并由狒狒吸入后甲状腺中无游离锝固定在体内检查标记的稳定性。采用直接同位素技术比较在接受一级预防治疗的4名HIV患者中,使用两种雾化器雾化300mg 99m Tc标记的乙磺酸盐喷他脒后的肺部沉积情况。

结果

Fisoneb的计数中值空气动力学直径和质量中值空气动力学直径(MMAD)高于Respirgard II。然而,Fisoneb的MMAD仍处于外周沉积的最佳范围内。在一名患者中,与Fisoneb(雾化器中原始剂量的10.2%)相比,使用Respirgard II时喷他脒的肺部负荷更高(雾化器中原始剂量的13%)。与Respirgard II(平均值 = 3.8%)相比,其他3名患者使用Fisoneb时获得了更好的结果(平均值 = 14.3%)。在所有4名患者中,与Respirgard II(平均值 = 2.6%)相比,Fisoneb的胃污染更高(平均值 = 5.2%)。两种设备均未观察到咳嗽和支气管痉挛。

结论

本研究表明,Fisoneb是一种实用且廉价的雾化器,在用于喷他脒雾化的临床研究中已被证明是有效的,可使药物的颗粒大小分布和肺部沉积正确。我们认为,对于任何类型的雾化器,都应推荐进行此类评估气溶胶特性的研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验